Coronavirus SARS-CoV2: BESSY II data accelerate drug development
Schematic representation of the coronavirus protease. The enzyme comes as a dimer consisting of two identical molecules. A part of the dimer is shown in colour (green and purple), the other in grey. The small molecule in yellow binds to the active centre of the protease and could be used as blueprint for an inhibitor. © H. Tabermann/HZB
Filmclip: At BESSY II, the main protease of SARS-CoV2 has been decoded. This might help to develop drugs. © HG Medien/HZB
01:11A coronavirus is keeping the world in suspense. SARS-CoV-2 is highly infectious and can cause severe pneumonia with respiratory distress (COVID-19). Scientists are doing research in order to prevent the viruses from multiplying. A team from the University of Lübeck and from Helmholtz Centre for Infection Research (HZI) has now found a promising approach. Using the high-intensity X-ray light from the Berlin synchrotron source BESSY II, they have decoded the three-dimensional architecture of the main protease of SARS-CoV-2. This protein is involved in the reproduction of the virus. Analysing its 3D architecture allows the systematic development of drugs which inhibit the reproduction of the virus.
Teams around the world are working hard to develop active substances against SARS-CoV-2. The structural analysis of functional proteins of the virus is very helpful for this goal. The function of a protein is closely related to its 3D architecture. If this 3D architecture is known, it is possible to identify specific points of attack for active substances.
Inhibiting the reproduction
A special protein is involved in the reproduction of the virus: the viral main protease (Mpro or also 3CLpro). A team led by Prof. Dr. Rolf Hilgenfeld, University of Lübeck, has now decoded the 3D architecture of the main protease of SARS-CoV-2. The researchers have used the high-intensity X-ray light from the BESSY II facility of the Helmholtz-Zentrum Berlin.
Fast track at BESSY II
"For such issues of highest relevance, we can offer fast track access to our instruments", says Dr. Manfred Weiss, who heads the Research Group Macromolecular Crystallography (MX) at HZB. At the so-called MX instruments tiny protein crystals can be analysed with highly brilliant X-ray light. The images contain information about the 3D architecture of the protein molecules. The complex shape of the protein molecule and its electron density is then calculated by computer algorithms.
Targets for active substances
The 3D architecture provides concrete starting points for developing active substances or inhibitors. These drugs could dock specifically to target points of the macromolecule and impede its function. Rolf Hilgenfeld is a world-renowned expert in the field of virology and already developed an inhibitor against the SARS-virus during the 2002/2003 SARS pandemic. In 2016, he succeeded in deciphering an enzyme of the Zika virus.
Science, 20. March 2020: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Linlin Zhang, Daizong Lin, Xinyuanyuan Sun, Ute Curth, Christian Drosten, Lucie Sauerhering, Stephan Becker, Katharina Rox, Rolf Hilgenfeld
DOI: 10.1126/science.abb3405
- Metallic nanocatalysts: what really happens during catalysisUsing a combination of spectromicroscopy at BESSY II and microscopic analyses at DESY's NanoLab, a team has gained new insights into the chemical behaviour of nanocatalysts during catalysis. The nanoparticles consisted of a platinum core with a rhodium shell. This configuration allows a better understanding of structural changes in, for example, rhodium-platinum catalysts for emission control. The results show that under typical catalytic conditions, some of the rhodium in the shell can diffuse into the interior of the nanoparticles. However, most of it remains on the surface and oxidises. This process is strongly dependent on the surface orientation of the nanoparticle facets.
- Key technology for a future without fossil fuelsIn June and July 2025, catalyst researcher Nico Fischer spent some time at HZB. It was his sabbatical, he was relieved of his duties as Director of the Catalysis Institute in Cape Town for several months and was able to focus on research only. His institute is collaborating with HZB on two projects that aim to develop environmentally friendly alternatives using innovative catalyst technologies. The questions were asked by Antonia Rötger, HZB.
- 5000th patient treated with protons for eye tumoursFor more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.